Chronic myeloid leukemia: First-line drug of choice

American Journal of Hematology

Volumn 91, Issue 1, 2016, Pages 59-66

  Jabbour, Elias ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BOSUTINIB; CYTARABINE; DASATINIB; IMATINIB; NILOTINIB; ORGANIC CATION TRANSPORTER 1; PEGINTERFERON ALPHA2A; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COMORBIDITY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; LEUKEMIA REMISSION; MULTICENTER STUDY (TOPIC); MUSCLE CRAMP; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PATIENT MONITORING; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG RESISTANCE; ENZYMOLOGY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;

ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84954289990     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24249     Document Type: Article

References (79)

1. Melo JV. The molecular biology of chronic myeloid leukaemia. Leukemia 1996;10:751-756.
2. Shuai K, Halpern J, ten Hoeve J, et al. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996;13:247-254.
3. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The BCR-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA 1995;92:11746-11750.
4. American Cancer Society. Cancer Facts and Figures 2015. Atlanta: American Cancer Society; 2015.
5. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 2012;118:3123-3127.
6. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993;82:398-407.
7. Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med 1995;122:254-261.
8. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223-229.
9. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-566.
10. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
11. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
12. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. ASH Annual Meeting Abstracts 2009;114:1126.
13. Cortes JE, Kantarjian HM, Goldberg SL, et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses. J Clin Oncol 2009;27:4754-4759.
14. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010;28:424-430.
15. Baccarani M, Druker BJ, Branford S, et al. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int J Hematol 2014;99:616-624.
16. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011;29:1634-1642.
17. Baccarani M, Rosti G, Castagnetti F, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: A European Leukemia Net Study. Blood 2009;113:4497-4504.
18. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010;363:2511-2521.
19. Cortes J, Quintas-Cardama A, Jones D, et al. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: A randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer 2011;117:572-580.
20. Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006;354:2594-2596.
21. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-2541.
22. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-3212.
23. Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: Follow-up of a phase 3 study. Blood 2014;123:2317-2324.
24. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-2270.
25. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014;123:494-500.
26. Cortes J, Saglio G, Baccarani M, et al. Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). Blood (ASH Annual Meeting Abstracts) 2014;124:152.
27. O'Brien SG, Hedgley C, Adams S, et al. Spirit 2: An NCRI randomized study comparing dasatinib with imatinib in patients with newly diagnosed CML. Blood (ASH Annual Meeting Abstracts) 2014;124:517.
28. Weisberg E, Manley P, Mestan J, et al. AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL. Br J Cancer 2006;94:1765-1769.
29. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-2551.
30. Kantarjian HM, Giles F, Gatterman N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-3546.
31. Saglio G, Kim DW. Issaragrisil, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259.
32. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow up. Leukemia 2012;26:2197-2203.
33. Larson RA, Kim DW, Jootar S, et al. ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM). J Clin Oncol (Meeting Abstracts) 2014;32:7073.
34. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant BCR-Abl+ neoplastic cells. Cancer Res 2006;66:11314-11322.
35. Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118:4567-4576.
36. Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial. J Clin Oncol 2012;30:3486-3492.
37. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401-412.
38. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369:1783-1796.
39. Jain P, Kantarjian H, Jabbour E, et al. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: A phase 2 study. Lancet Haematol 2015;2:e376-e383.
40. Lipton JH. Epic: A phase 3 trial of ponatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). ASH 2014 Abstract 519. 201.
41. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusions in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-3914.
42. Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimized the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010;116:377-386.
43. Sprycel (dasatinib) Package Insert. Princeton, NJ. Bristol-Myers Squibb Company. 5/2014.
44. Quintas-Cardama A, Han X, Kantarjian H, et al. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114:261-263.
45. Tasigna (nilotinib) Package Insert. East Hanover, NJ. Novartis Pharmaceuticals Corporation. 1/2014.
46. Aichberger KJ, Herndlhofer S, Schernthaner G, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86:533-539.
47. Quintas-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 2012;12:337-340.
48. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol 2011;86:610-611.
49. Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013;27:1310-1315.
50. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984;63:789-799.
51. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998;90:850-858.
52. White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007;110:4064-4072.
53. White DL, Dang P, Engler J, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010;28:2761-2767.
54. White DL, Radich J, Soverini S, et al. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses, and lower failure rates, than those randomized to standard-dose. Haematologica 2012;97:907-914.
55. Yeung DT, Vidovic L, Tang C, et al. KIR2DL5B genotype independently predicts poor outcomes in CML-CP patients switched to nilotinib after suboptimal responses to imatinib and may refine prognosis in patients with EMR failure. Blood (ASH Annual Meeting Abstracts) 2014;124:814.
56. Marin D, Gabriel IH, Ahmad S, et al. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia 2012;26:296-302.
57. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
58. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium-The just price. J Clin Oncol 2013;31:3600-3604.
59. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med 2011;364:2060-2065.
60. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-4442.
61. Gambacorti-Passerini C, Antolini L, Mahon X, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011;103:553-561.
62. Gleevec (imatinib) Package Insert. East Hanover, NJ. Novartis Pharmaceuticals Corporation. 10/2013.
63. Parikh P. Report of chronic myeloid leukemia in chronic phase from Tata Memorial Hospital, Mumbai, 2002-2008. Indian J Med Paediatr Oncol 2013;34:164-167.
64. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-6051.
65. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-884.
66. Testoni N, Marzocchi G, Luatti S, et al. Chronic myeloid leukemia: A prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood 2009;114:4939-4943.
67. Kantarjian H, Cortes J. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:1512-1516.
68. Kantarjian HM, Shan J, Jones D, et al. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol 2009;27:3659-3663.
69. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012;30:232-238.
70. Jain P, Kantarjian H, Nazha A, et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 2013;121:4867-4874.
71. Neelakantan P, Gerrard G, Lucas C, et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 2013;121:2739-2742.
72. Nazha A, Kantarjian H, Jain P, et al. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica 2013;98:1686-1688.
73. Branford S, Roberts N, Yeung DT, et al. Any BRC-ABL reduction below 10% at 6 months of therapy significantly improves outcome for CML patients with a poor response at 3 months. Blood 2013;122:254 (ASH Annual Meeting Abstracts).
74. Jabbour E, Kantarjian HM, O'Brien S, et al. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: What is the optimal response? J Clin Oncol 2011;29:4260-4265.
75. Cortes JE, De Souza CA, Lopez JL, et al. Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with suboptimal cytogenetic response on imatinib: First results of the LASOR trial. Blood 2013;122:95 (ASH Annual Meeting Abstracts).
76. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicenter Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-1035.
77. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study. Blood 2013;122:515-522.
78. Mahon F, Richter J, Guilhot JG, et al. Interim analysis of a pan european stop tyrosine kinase inhibitor trial in chronic myeloid leukemia: The EURO-SKI Study. Blood (ASH Annual Meeting Abstracts) 2014;124:151.
79. Rea D, Nicolini FE, Tulliez M, et al. Dasatinib or nilotinib discontinuation in chronic phase (CP)-chronic myeloid leukemia (CML) patients (pts) with durably undetectable BCR-ABL transcripts: Interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 Months-on Behalf of the French CML Group Filmc. Blood (ASH Annual Meeting Abstracts) 2014;124:811.